Growth Story Still Intact For Roivant Sciences Ltd (ROIV)

Roivant Sciences Ltd (ROIV) concluded trading on Thursday at a closing price of $10.76, with 3.78 million shares of worth about $40.64 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -8.89% during that period and on May 15, 2025 the price saw a gain of about 0.84%. Currently the company’s common shares owned by public are about 719.63M shares, out of which, 439.45M shares are available for trading.

Stock saw a price change of -2.45% in past 5 days and over the past one month there was a price change of 6.96%. Year-to-date (YTD), ROIV shares are showing a performance of -9.04% which decreased to -3.76% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $8.73 but also hit the highest price of $13.06 during that period. The average intraday trading volume for Roivant Sciences Ltd shares is 6.68 million. The stock is currently trading -1.81% below its 20-day simple moving average (SMA20), while that difference is up 1.94% for SMA50 and it goes to -4.41% lower than SMA200.

Roivant Sciences Ltd (NASDAQ: ROIV) currently have 719.63M outstanding shares and institutions hold larger chunk of about 68.82% of that.

The stock has a current market capitalization of $7.68B and its 3Y-monthly beta is at 1.16. It has posted earnings per share of -$0.14 in the same period. It has Quick Ratio of 37.91 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ROIV, volatility over the week remained 3.47% while standing at 2.94% over the month.

Stock’s fiscal year EPS is expected to drop by -109.96% while it is estimated to decrease by -114.71% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wolfe Research on February 15, 2024 offering an Outperform rating for the stock and assigned a target price of $17 to it. Coverage by Piper Sandler stated Roivant Sciences Ltd (ROIV) stock as an Overweight in their note to investors on January 05, 2024, suggesting a price target of $20 for the stock. On December 12, 2023, Deutsche Bank Initiated their recommendations, while on October 17, 2023, Guggenheim Initiated their ratings for the stock with a price target of $17. Stock get a Neutral rating from BofA Securities on June 08, 2023.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.